RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort

Affiliations

• ¹ NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. jennifer.osullivan@rdm.ox.ac.uk.
• ² Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, UK. jennifer.osullivan@rdm.ox.ac.uk.
• ³ Astex Pharmaceuticals, Inc., Pleasanton, CA, USA.
• ⁴ Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
• ⁵ CTI BioPharma Corp., Seattle, WA, USA.
• ⁶ Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, UK.
• ⁷ Washington University School of Medicine, Saint Louis, MO, USA.
• ⁸ Precision BioSciences, Inc., Durham, NC, USA.
• ⁹ Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
• ¹⁰ NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
• ¹¹ NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. adam.mead@imm.ox.ac.uk.